Moderna : ESCMID 2026 (mRNA-1345 Phase 3 RSV revaccination 60+ study)

Published: 2026-04-19 08:20:07 ET MRNA

Published on 04/19/2026 at 08:20 am EDT

Mihir Desai, Jose Cardona, Shishir Khetan, Shraddha Mehta, Archana Kapoor, Aghogho Okparavero, Zhantao Lin, Frances Priddy

April 18, 2026

Presented at the European Society of Clinical Microbiology and Infectious Diseases Munich, Germany

Mihir Desai, Shraddha Mehta, Aghogho Okparavero, Zhantao Lin, and Frances Priddy are employees of Moderna, Inc., and hold stock/stock options in the company. Archana Kapoor was an employee of Moderna, Inc., and held stock/stock options in the company. All relevant financial disclosures have been mitigated. All other authors have no conflicts of interest to declare.

Medical writing and editorial assistance were provided by MEDiSTRAVA in accordance with Good Publication Practice (GPP 2022) guidelines, funded by Moderna, Inc., and under the direction of the authors

This study was funded by Moderna, Inc.

Additional Information

Please scan the QR code for a copy of the oral presentation and related conference materials

Copies of this oral presentation obtained through this QR code are for personal

use only and may not be reproduced without written permission of the authors

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: target product profile; efficacy and safety; and the potential for regulatory approval. In some cases, forward-looking

statements can be identified by terminology such as "will," "may," "should," "expects," "intends,"

"plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those described in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at https://www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments, or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.

Respiratory syncytial virus (RSV) is a common respiratory pathogen that causes significant global disease

burden each year, including among older adults1-3

RSV vaccines are currently licensed as a single dose in adults; however, like natural infection, protection provided by vaccination is not expected to be lifelong

Vaccine effectiveness declines over time, with reduced protection observed by the second RSV season

across clinical trials and real-world studies4,5

- Real-world effectiveness studies (primarily US-based) show declining protection following a single RSV vaccine dose, with effectiveness against RSV-related hospitalization of 67% to 83% within 6 months,

declining to 42% after ≥12 months6

Declining effectiveness is more pronounced in immunocompromised individuals7

1. Testaert H, et al. Clin Microbiol Infect. 2021;27(6):897-903. 2. Savic M, et al. Influenza Other Respir Viruses. 2023;17(1):e13031. 3. Shi T, et al. J Infect Dis. 2020;222(suppl 7):S577-S583; 4. Kelleher K, et al. Ther Adv Vaccines Immunother. 2025;13:25151355241310601. 5. Trusinska D, et al. Lancet Reg Health Eur. 2026;64:101623. 6. Link-Gelles R, et al. 221. Open Forum Infect Dis. 2026;13(suppl 1):ofaf695.079. 7. Bajema KL, et al. JAMA Intern Med. 2026;186(1):78-88.

Desai M, et al. Safety and immunogenicity of heterologous RSV revaccination with mRNA-1345 after primary vaccination with protein-based vaccine.

Presented at: ESCMID Global 2026; 17-21 April 2026; Munich, Germany.

mRNA-1345 (mRESVIA; Moderna, Inc.) is an mRNA vaccine approved in multiple regions for the prevention of RSV-LRTD in adults aged ≥60 years and in adults aged 18 to 59 years who are at increased risk for RSV-LRTD

RSV neutralizing antibody responses are correlated with vaccine efficacy, with higher titers associated with greater protection1

Immunobridging of RSV neutralizing antibody responses to the pivotal Phase 2/3 efficacy study supported approval in adults aged 18 to 59 years at increased risk2

Homologous revaccination with mRNA-1345 at 12 or 24 months has demonstrated noninferior RSV nAb responses in Phase 3 studies3,4

Here, we present interim findings from an ongoing heterologous revaccination study with mRNA-1345

LNP, lipid nanoparticle; LRTD, lower respiratory tract disease; nAb, neutralizing antibody; RSV, respiratory syncytial virus.

1. Ma C, et al. Nat Commun. 2025;16(1):6118. 2. Mayer EF, et al. Clin Infect Dis. 2026;81(6):e708-e716. doi:10.1093/cid/ciaf292. 3. Goswami J, et al. Clin Infect Dis. Published online September 23, 2025. doi:10.1093/cid/ciaf515. 4. Desai M, et al. P5040. Presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress; 11-15 April 2025; Vienna, Austria.

Desai M, Cardona J, Khetan S, et al. Safety and immunogenicity of heterologous RSV revaccination with mRNA-1345 after primary vaccination with protein-based vaccine. Presented at: ESCMID Global 2026; 17 - 21 April 2026; Munich, Germany.

Disclaimer

Moderna Inc. published this content on April 19, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 19, 2026 at 12:19 UTC.